Cargando…
Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy
Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with th...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
The Royal Society
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696110/ https://www.ncbi.nlm.nih.gov/pubmed/18644768 http://dx.doi.org/10.1098/rsta.2008.0106 |
_version_ | 1782168253434429440 |
---|---|
author | Lehotzky, A. Tőkési, N. Gonzalez-Alvarez, I. Merino, V. Bermejo, M. Orosz, F. Lau, P. Kovacs, G.G. Ovádi, J. |
author_facet | Lehotzky, A. Tőkési, N. Gonzalez-Alvarez, I. Merino, V. Bermejo, M. Orosz, F. Lau, P. Kovacs, G.G. Ovádi, J. |
author_sort | Lehotzky, A. |
collection | PubMed |
description | Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the structural and functional characteristics of the microtubule system. Understanding the actions of these two potential effectors on the microtubule system could be the clue for early diagnosis and improvement of cancer therapy. |
format | Text |
id | pubmed-2696110 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | The Royal Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-26961102009-10-13 Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy Lehotzky, A. Tőkési, N. Gonzalez-Alvarez, I. Merino, V. Bermejo, M. Orosz, F. Lau, P. Kovacs, G.G. Ovádi, J. Philos Trans A Math Phys Eng Sci Review Cancer continues to be one of the major health and socio-economic problems worldwide, despite considerable efforts to improve its early diagnosis and treatment. The identification of new constituents as biomarkers for early diagnosis of neoplastic cells and the discovery of new type of drugs with their mechanistic actions are crucial to improve cancer therapy. New drugs have entered the market, thanks to industrial and legislative efforts ensuring continuity of pharmaceutical development. New targets have been identified, but cancer therapy and the anti-cancer drug market still partly depend on anti-mitotic agents. The objective of this paper is to show the effects of KAR-2, a potent anti-mitotic compound, and TPPP/p25, a new unstructured protein, on the structural and functional characteristics of the microtubule system. Understanding the actions of these two potential effectors on the microtubule system could be the clue for early diagnosis and improvement of cancer therapy. The Royal Society 2008-07-21 2008-10-13 /pmc/articles/PMC2696110/ /pubmed/18644768 http://dx.doi.org/10.1098/rsta.2008.0106 Text en Copyright © 2008 The Royal Society http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Lehotzky, A. Tőkési, N. Gonzalez-Alvarez, I. Merino, V. Bermejo, M. Orosz, F. Lau, P. Kovacs, G.G. Ovádi, J. Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy |
title | Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy |
title_full | Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy |
title_fullStr | Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy |
title_full_unstemmed | Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy |
title_short | Progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy |
title_sort | progress in the development of early diagnosis and a drug with unique pharmacology to improve cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2696110/ https://www.ncbi.nlm.nih.gov/pubmed/18644768 http://dx.doi.org/10.1098/rsta.2008.0106 |
work_keys_str_mv | AT lehotzkya progressinthedevelopmentofearlydiagnosisandadrugwithuniquepharmacologytoimprovecancertherapy AT tokesin progressinthedevelopmentofearlydiagnosisandadrugwithuniquepharmacologytoimprovecancertherapy AT gonzalezalvarezi progressinthedevelopmentofearlydiagnosisandadrugwithuniquepharmacologytoimprovecancertherapy AT merinov progressinthedevelopmentofearlydiagnosisandadrugwithuniquepharmacologytoimprovecancertherapy AT bermejom progressinthedevelopmentofearlydiagnosisandadrugwithuniquepharmacologytoimprovecancertherapy AT oroszf progressinthedevelopmentofearlydiagnosisandadrugwithuniquepharmacologytoimprovecancertherapy AT laup progressinthedevelopmentofearlydiagnosisandadrugwithuniquepharmacologytoimprovecancertherapy AT kovacsgg progressinthedevelopmentofearlydiagnosisandadrugwithuniquepharmacologytoimprovecancertherapy AT ovadij progressinthedevelopmentofearlydiagnosisandadrugwithuniquepharmacologytoimprovecancertherapy |